Key result
Low-dose corticosteroids significantly improved the median percentage change in eGFR at 4 weeks compared to no steroids (24% vs 5%), but did not favorably affect long-term renal outcomes.
Why the study?
Does low-dose corticosteroid therapy improve short- and long-term renal outcomes in patients with cholesterol crystal embolism?
Cohort (n=51)
Does low-dose corticosteroid therapy improve short- and long-term renal outcomes in patients with cholesterol crystal embolism?
Absolute Event Rate: 24% vs 5%
p-value: p=statistically significant
Low-dose corticosteroid therapy improves short-term renal function in patients with cholesterol crystal embolism but does not provide long-term renal benefits.
No takes yet. Share an insight, caveat, or question.
Short-term eGFR gains with low-dose corticosteroids should not yet change practice; leaves open long-term renal benefit in cholesterol crystal embolism.
Nakayama et al. (2011) conducted a cohort in renal cholesterol crystal embolism (CCE) (n=51). Corticosteroids vs. no steroid therapy was evaluated on median % change in eGFR between diagnosis and 4 weeks after diagnosis (p=statistically significant). Low-dose corticosteroids significantly improved the median percentage change in eGFR at 4 weeks compared to no steroids (24% vs 5%), but did not favorably affect long-term renal outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: